Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors

Uddin, Md. Jashim; Crews, Brenda C.; Xu, Shu; Ghebreselasie, Kebreab; Daniel, Cristina K.; Kingsley, Philip J.; Banerjee, Surajit; Marnett, Lawrence J.

doi:10.1021/acschembio.6b00560

Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors

Journal Article · Mon Sep 19 00:00:00 EDT 2016 · ACS Chemical Biology

DOI:https://doi.org/10.1021/acschembio.6b00560· OSTI ID:1333962

Uddin, Md. Jashim ^[1]; Crews, Brenda C. ^[1]; Xu, Shu ^[1]; Ghebreselasie, Kebreab ^[1]; Daniel, Cristina K. ^[1]; Kingsley, Philip J. ^[1]; Banerjee, Surajit ^[2]; Marnett, Lawrence J. ^[1]

Vanderbilt Univ., Nashville, TN (United States)
Cornell Univ., Ithaca, NY (United States)

Targeted delivery of chemotherapeutic agents to tumors has been explored as a means to increase the selectivity and potency of cytotoxicity. Most efforts in this area have exploited the molecular recognition of proteins highly expressed on the surface of cancer cells followed by internalization. A related approach that has received less attention is the targeting of intracellular proteins by ligands conjugated to anticancer drugs. An attractive target for this approach is the enzyme cyclooxygenase-2 (COX-2), which is highly expressed in a range of malignant tumors. Herein, we describe the synthesis and evaluation of a series of chemotherapeutic agents targeted to COX-2 by conjugation to indomethacin. Detailed characterization of compound 12, a conjugate of indomethacin with podophyllotoxin, revealed highly potent and selective COX-2 inhibition in vitro and in intact cells. Kinetics and X-ray crystallographic studies demonstrated that compound 12 is a slow, tight-binding inhibitor that likely binds to COX-2’s allosteric site with its indomethacin moiety in a conformation similar to that of indomethacin. Compound 12 exhibited cytotoxicity in cell culture similar to that of podophyllotoxin with no evidence of COX-2-dependent selectivity. However, in vivo, compound 12 accumulated selectively in and more effectively inhibited the growth of a COX-2-expressing xenograft compared to a xenograft that did not express COX-2. Compound 12, which we have named chemocoxib A, provides proof-of-concept for the in vivo targeting of chemotherapeutic agents to COX-2 but suggests that COX-2-dependent selectivity may not be evident in cell culture-based assays.

View Accepted Manuscript (DOE)

Research Organization:: Argonne National Laboratory (ANL), Argonne, IL (US)

Sponsoring Organization:: National Institutes of Health (NIH); USDOE Office of Science (SC)

Grant/Contract Number:: AC02-06CH11357

OSTI ID:: 1333962

Journal Information:: ACS Chemical Biology, Journal Name: ACS Chemical Biology Journal Issue: 11 Vol. 11; ISSN 1554-8929

Publisher:: American Chemical Society (ACS)Copyright Statement

Country of Publication:: United States

Language:: ENGLISH

References (35)

Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance Neumann, Wilma; Crews, Brenda C.; Sárosi, Menyhárt B. ChemMedChem, Vol. 10, Issue 1 https://doi.org/10.1002/cmdc.201402353	journal	October 2014
COX-2 and colon cancer Taketo, M. M. Inflammation Research, Vol. 47, Issue 0 https://doi.org/10.1007/s000110050295	journal	December 1998
Cyclooxygenase-2 and Gastric Cancer Thiel, Alexandra; Mrena, Johanna; Ristimäki, Ari Cancer and Metastasis Reviews, Vol. 30, Issue 3-4 https://doi.org/10.1007/s10555-011-9312-1	journal	October 2011
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure Shirvani, Vivian N.; Ouatu-Lascar, Rodica; Kaur, Baljeet S. Gastroenterology, Vol. 118, Issue 3 https://doi.org/10.1016/S0016-5085(00)70254-X	journal	March 2000
COX-2 as a target for cancer chemotherapy Ghosh, Nilanjan; Chaki, Rituparna; Mandal, Vivekananda Pharmacological Reports, Vol. 62, Issue 2 https://doi.org/10.1016/S1734-1140(10)70262-0	journal	March 2010
Podophyllotoxin analogues active versus Trypanosoma brucei Uddin, Md. Jashim; Smithson, David C.; Brown, Kristin M. Bioorganic & Medicinal Chemistry Letters, Vol. 20, Issue 5 https://doi.org/10.1016/j.bmcl.2010.01.009	journal	March 2010
Detection of Non-Melanoma Skin Cancer by in vivo Fluorescence Imaging with Fluorocoxib A Ra, Hyejun; González-González, Emilio; Uddin, Md. Jashim Neoplasia, Vol. 17, Issue 2 https://doi.org/10.1016/j.neo.2014.12.009	journal	February 2015
Engineering Folate–Drug Conjugates to Target Cancer: From Chemistry to Clinic Vlahov, Iontcho R.; Leamon, Christopher P. Bioconjugate Chemistry, Vol. 23, Issue 7 https://doi.org/10.1021/bc2005522	journal	June 2012
Design, Synthesis, and Structure–Activity Relationship Studies of Fluorescent Inhibitors of Cycloxygenase-2 as Targeted Optical Imaging Agents Uddin, Md. Jashim; Crews, Brenda C.; Ghebreselasie, Kebreab Bioconjugate Chemistry, Vol. 24, Issue 4 https://doi.org/10.1021/bc300693w	journal	March 2013
Molecular Basis of the Time-Dependent Inhibition of Cyclooxygenases by Indomethacin ^† Prusakiewicz, Jeffery J.; Felts, Andrew S.; Mackenzie, Bonnie S. Biochemistry, Vol. 43, Issue 49 https://doi.org/10.1021/bi048534q	journal	December 2004
Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors Kalgutkar, Amit S.; Marnett, Alan B.; Crews, Brenda C. Journal of Medicinal Chemistry, Vol. 43, Issue 15 https://doi.org/10.1021/jm000004e	journal	July 2000
Substrate-Selective Inhibition of Cyclooxygenase-2: Development and Evaluation of Achiral Profen Probes Windsor, Matthew A.; Hermanson, Daniel J.; Kingsley, Philip J. ACS Medicinal Chemistry Letters, Vol. 3, Issue 9 https://doi.org/10.1021/ml3001616	journal	July 2012
The 2′-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor Blobaum, Anna L.; Uddin, Md. Jashim; Felts, Andrew S. ACS Medicinal Chemistry Letters, Vol. 4, Issue 5 https://doi.org/10.1021/ml400066a	journal	March 2013
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents Kurumbail, Ravi G.; Stevens, Anna M.; Gierse, James K. Nature, Vol. 384, Issue 6610 https://doi.org/10.1038/384644a0	journal	December 1996
Chemoprevention strategies for pancreatic cancer Stan, Silvia D.; Singh, Shivendra V.; Brand, Randall E. Nature Reviews Gastroenterology & Hepatology, Vol. 7, Issue 6 https://doi.org/10.1038/nrgastro.2010.61	journal	May 2010
Antibody–drug conjugates as novel anti-cancer chemotherapeutics Peters, Christina; Brown, Stuart Bioscience Reports, Vol. 35, Issue 4 https://doi.org/10.1042/BSR20150089	journal	July 2015
Competition and allostery govern substrate selectivity of cyclooxygenase-2 Mitchener, Michelle M.; Hermanson, Daniel J.; Shockley, Erin M. Proceedings of the National Academy of Sciences, Vol. 112, Issue 40 https://doi.org/10.1073/pnas.1507307112	journal	September 2015
Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors Kalgutkar, A. S.; Crews, B. C.; Rowlinson, S. W. Proceedings of the National Academy of Sciences, Vol. 97, Issue 2 https://doi.org/10.1073/pnas.97.2.925	journal	January 2000
Molecular Basis for Cyclooxygenase Inhibition by the Non-steroidal Anti-inflammatory Drug Naproxen Duggan, Kelsey C.; Walters, Matthew J.; Musee, Joel Journal of Biological Chemistry, Vol. 285, Issue 45 https://doi.org/10.1074/jbc.M110.162982	journal	September 2010
Human Cyclooxygenase-2 Is a Sequence Homodimer That Functions as a Conformational Heterodimer Dong, Liang; Vecchio, Alex J.; Sharma, Narayan P. Journal of Biological Chemistry, Vol. 286, Issue 21 https://doi.org/10.1074/jbc.M111.231969	journal	April 2011
PRODRG : a tool for high-throughput crystallography of protein–ligand complexes Schüttelkopf, Alexander W.; van Aalten, Daan M. F. Acta Crystallographica Section D Biological Crystallography, Vol. 60, Issue 8 https://doi.org/10.1107/S0907444904011679	journal	July 2004
Solving structures of protein complexes by molecular replacement with Phaser McCoy, Airlie J. Acta Crystallographica Section D Biological Crystallography, Vol. 63, Issue 1 https://doi.org/10.1107/S0907444906045975	journal	December 2006
Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard Terwilliger, Thomas C.; Grosse-Kunstleve, Ralf W.; Afonine, Pavel V. Acta Crystallographica Section D Biological Crystallography, Vol. 64, Issue 1 https://doi.org/10.1107/S090744490705024X	journal	December 2007
XDS Kabsch, Wolfgang Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2 https://doi.org/10.1107/S0907444909047337	journal	January 2010
PHENIX: a comprehensive Python-based system for macromolecular structure solution Adams, Paul D.; Afonine, Pavel V.; Bunkóczi, Gábor Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2, p. 213-221 https://doi.org/10.1107/S0907444909052925	journal	January 2010
Features and development of Coot Emsley, P.; Lohkamp, B.; Scott, W. G. Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 4 https://doi.org/10.1107/S0907444910007493	journal	March 2010
Selective Visualization of Cyclooxygenase-2 in Inflammation and Cancer by Targeted Fluorescent Imaging Agents Uddin, Md. Jashim; Crews, Brenda C.; Blobaum, Anna L. Cancer Research, Vol. 70, Issue 9 https://doi.org/10.1158/0008-5472.CAN-09-2664	journal	April 2010
Gastrin-Induced Cyclooxygenase-2 Expression in Barrett’s Carcinogenesis Abdalla, Salem I.; Lao-Sirieix, Pierre; Novelli, Marco R. Clinical Cancer Research, Vol. 10, Issue 14 https://doi.org/10.1158/1078-0432.CCR-04-0015	journal	July 2004
Fluorinated COX-2 Inhibitors as Agents in PET Imaging of Inflammation and Cancer Uddin, Md. Jashim; Crews, Brenda C.; Ghebreselasie, Kebreab Cancer Prevention Research, Vol. 4, Issue 10 https://doi.org/10.1158/1940-6207.CAPR-11-0120	journal	September 2011
Molecular Imaging of Cyclooxygenase-2 in Canine Transitional Cell Carcinomas In Vitro and In Vivo Cekanova, M.; Uddin, M. J.; Bartges, J. W. Cancer Prevention Research, Vol. 6, Issue 5 https://doi.org/10.1158/1940-6207.CAPR-12-0358	journal	March 2013
Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids Zou, Hechang; Yuan, Chong; Dong, Liang Journal of Lipid Research, Vol. 53, Issue 7 https://doi.org/10.1194/jlr.M026856	journal	April 2012
Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy—Cancer and Leukemia Group B Trial 30203 Edelman, Martin J.; Watson, Dee; Wang, Xiaofei Journal of Clinical Oncology, Vol. 26, Issue 6 https://doi.org/10.1200/JCO.2007.13.8081	journal	February 2008
Biology of Cox-2: An Application in Cancer Therapeutics Khan, Zakir; Khan, Noor; P. Tiwari, Ram Current Drug Targets, Vol. 12, Issue 7 https://doi.org/10.2174/138945011795677764	journal	June 2011
Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention Moreira, Leticia; Castells, Antoni Current Drug Targets, Vol. 12, Issue 13 https://doi.org/10.2174/138945011798184218	journal	December 2011
Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma Kao, J.; Sikora, A.; Fu, S. Current Cancer Drug Targets, Vol. 9, Issue 8 https://doi.org/10.2174/156800909790192437	journal	December 2009

Cited By (5)

Strategy to targeting the immune resistance and novel therapy in colorectal cancer Gang, Wang; Wang, Jun-Jie; Guan, Rui Cancer Medicine, Vol. 7, Issue 5 https://doi.org/10.1002/cam4.1386	journal	April 2018
Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site Xu, Shu; Uddin, Md. Jashim; Banerjee, Surajit Journal of Biological Chemistry, Vol. 294, Issue 22 https://doi.org/10.1074/jbc.ra119.007405	journal	April 2019
Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018) Mahboubi Rabbani, Sayyed Mohammad Ismail; Zarghi, Afshin Expert Opinion on Therapeutic Patents, Vol. 29, Issue 6 https://doi.org/10.1080/13543776.2019.1623880	journal	May 2019
Immunotherapy for colorectal cancer: where are we heading? Basile, Debora; Garattini, Silvio Ken; Bonotto, Marta Expert Opinion on Biological Therapy, Vol. 17, Issue 6 https://doi.org/10.1080/14712598.2017.1315405	journal	April 2017
BindingDB Entry 7608: Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors. No authors listed BindingDB https://doi.org/10.7270/q23777jp	dataset	January 2016

Figures / Tables (7)

Similar Records

Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site

Journal Article · Thu Apr 18 00:00:00 EDT 2019 · Journal of Biological Chemistry · OSTI ID:1530995

Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation

Journal Article · Sun Sep 10 00:00:00 EDT 2006 · Experimental Cell Research · OSTI ID:20858020

Structural Basis of Enantioselective Inhibition of Cyclooxygenase-1 by S-[alpha]-Substituted Indomethacin Ethanolamides

Journal Article · Wed Jan 14 23:00:00 EST 2009 · J. Biol. Chem. · OSTI ID:1007653

Related Subjects

60 APPLIED LIFE SCIENCES
Cells
Conjugate acid-base pairs
Inhibition
Inhibitors
Tumors

Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors

Citation Formats

References (35)

Cited By (5)

Figures / Tables (7)

Similar Records

Related Subjects